Published in

Wiley, Cochrane Library, 12(2020), 2020

DOI: 10.1002/14651858.cd011748.pub3

Wiley, Cochrane Library, 2017

DOI: 10.1002/14651858.cd011748.pub2

Protocols

DOI: 10.1002/14651858.cd011748

Links

Tools

Export citation

Search in Google Scholar

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

Journal article published in 2015 by Amand F. Schmidt ORCID, John-Paul L. Carter, Lucy S. Pearce, John T. Wilkins, John P. Overington, Aroon D. Hingorani, Juan Pablo Casas
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

© 2015 The Cochrane Collaboration.This is the protocol for a review and there is no abstract. The objectives are as follows: Primary To quantify the short (24 weeks), medium (one year), and long-term (five year) effects of PCSK9MABs on lipid parameters and CVD risk. Secondary To quantify the safety of PCSK9 MABs, specifically focusing on the incidence of type 2 diabetes, cognitive function, and cancer. Additionally, we will determine if treatment should be tailored to certain patient subgroups that are more or less likely to benefit from PCSK9 MABs.